We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effect of darbepoetin alfa on endothelial progenitor cells and vascular reactivity in chronic kidney disease.
- Authors
Mohler, Emile R.; Lifeng Zhang; Medenilla, Elizabeth; Rogers, Wade; French, Benjamin; Bantly, Andrew; Moore, Jonni S.; Yonghong Huan; Murashima, Miho; Berns, Jeffrey S.
- Abstract
Endothelial progenitor cells (EPCs) are thought to be important for maintaining normal vascular function. We conducted a prospective study evaluating the effect of the erythropoiesis-stimulating agent darbepoetin alfa on EPCs and vascular function in patients with chronic kidney disease (CKD), with or without diabetes. Thirty subjects with CKD (20 subjects with type II diabetes mellitus and 10 without diabetes mellitus) received weekly subcutaneous administration of darbepoetin alfa for 4 weeks. EPCs were measured at baseline and 2 and 4 weeks after drug administration. Vascular function was measured with brachial ultrasound and cell activity was measured with a cell proliferation assay. Cells expressing CD133, CD34, CD146 and CD146/31 were significantly elevated (all p < 0.05), flow-mediated vasodilatation increased 2.1%, 95% CI: (0.4%, 3.8%) and colony-forming units increased twofold, 95% CI: (1.7, 2.3) after 4 weeks of treatment with darbepoetin alfa. Subjects with diabetes exhibited an increase in a subset of EPCs (CD133 + and 34+, p < 0.01 and p = 0.06, respectively), vasodilatation and proliferation. In conclusion, the administration of darbepoetin alfa for 4 weeks increased a subset of EPCs, improved endothelial function and increased cell proliferation, including those with diabetes, which is consistent with a favorable improvement in vascular health.
- Subjects
KIDNEY diseases; DIABETES; INTRAVASCULAR ultrasonography; VASCULAR diseases; ENDOTHELIUM; NEOVASCULARIZATION; VASODILATION
- Publication
Vascular Medicine, 2011, Vol 16, Issue 3, p183
- ISSN
1358-863X
- Publication type
Article
- DOI
10.1177/1358863X11408639